Recursion Pharmaceuticals, Inc. (RXRX): Total Liabilities
$343.26M
As of 2025-12-31
$297.67M
As of 2026-06-30
+16.8%
3-year compound annual growth
+43.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $343.26M | -17.0% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $413.82M | +117.5% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $190.26M | -11.7% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $215.48M | +219.7% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $67.41M | +19.2% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $56.56M | n/a | 2022-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $343.26M | -17.0% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $410.94M | +15.6% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $30.80M | -21.7% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $237.55M | -4.4% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $250.22M | +23.9% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $61.05M | +22.6% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $35.34M | -43.0% |
Compare RXRX, AUTL, BDTX, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗